Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

被引:0
|
作者
Soria, Anna [1 ]
Calvo, Mariona [2 ]
Casas, Meritxell [1 ]
Vidales, Zara [2 ]
Munoz-Martinez, Sergio [3 ,4 ]
Sapena, Victor [3 ,5 ,6 ]
Puigvehi, Marc [7 ]
Canillas, Lidia [7 ]
Guardeno, Raquel [8 ]
Gallego, Adolfo [9 ]
Minguez, Beatriz [4 ,6 ]
Horta, Diana [4 ,10 ]
Clos, Ariadna [11 ]
Montoliu, Silvia [12 ]
Roget, Merce [13 ]
Reig, Maria [3 ,4 ]
Vergara, Mercedes [1 ,4 ]
机构
[1] Univ Autonoma Barcelona, Parc Tauli Univ Hosp, Invest & Innovat Inst Parc Tauli I3PT, Dept Digest Dis, Sabadell, Spain
[2] Catalan Inst Oncol, Med Oncol Dept, Hospitalet, Barcelona, Spain
[3] Barcelona Univ, Clin Hosp, Barcelona Clin Liver Canc BCLC Grp, Liver Unit, Barcelona, Spain
[4] Liver Dis Network CIBERehd, Inst Carlos3, Biomed Res Ctr Digest, Madrid, Spain
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Med Stat Core Facil, Barcelona, Spain
[6] Univ Autonoma Barcelona, Univ Hosp Vall dHebron, Vall dHebron Inst Res VHIR, Liver Unit, Barcelona, Spain
[7] Hosp Mar Med Res Inst, Dept Digest Dis, Liver Unit, Barcelona, Spain
[8] Josep Trueta Univ Hosp, Catalan Inst Oncol, Med Oncol Dept, Girona, Spain
[9] St Pau i St Creu Univ Hosp, Dept Digest Dis, Barcelona, Spain
[10] Univ Hosp Mutua Terrassa, Barcelona Univ, Dept Gastroenterol, Terrassa, Spain
[11] Germans Trias i Pujol Univ Hosp, Dept Digest Dis, Badalona, Spain
[12] Joan XXIII Univ Hosp, Dept Digest Dis, Tarragona, Spain
[13] Consorci Sanit Terrassa, Dept Digest Dis, Liver Unit, Terrassa, Spain
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
sorafenib; elderly patients; hepatocellular carcinoma; overall survival; safety; outcome; CLINICAL CHARACTERISTICS; SAFETY; EFFICACY; PROGNOSIS; OUTCOMES; OLDER;
D O I
10.3389/fonc.2022.829483
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionThe first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. MethodsRetrospective multicentre study of HCC patients aged >= 75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. ResultsThe study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS>0 (45.3 vs 34.7%; STD: 38.2) differed significantly between patients receiving low and full doses. Median OS was 15.4 months (18.2 in BCLC-B vs 13.6 in BCLC-C). OS was not modified by comorbidities, age or period with more expertise. ConclusionsSorafenib appears to be safe in elderly patients with HCC. This is the first study to characterize the profile of elderly patients to be considered for systemic treatment. These findings could be used as the reference profile for elderly candidates for atezolizumab-bevacizumab.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Hepatocellular carcinoma treated with sorafenib
    Han, G.
    Zhao, Y.
    Qi, X.
    Fan, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) : 1347 - 1348
  • [42] Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
    Xiao-Chun Meng
    Bing-Hui Chen
    Jing-Jun Huang
    Wen-Sou Huang
    Ming-Yue Cai
    Jing-Wen Zhou
    Yong-Jian Guo
    Kang-Shun Zhu
    World Journal of Gastroenterology, 2018, (04) : 484 - 493
  • [43] Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib
    Lim, Seungtaek
    Han, Jungwoo
    Kim, Gun Min
    Han, Kwang-Hyub
    Choi, Hye Jin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (06) : 1024 - 1031
  • [44] Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
    Meng, Xiao-Chun
    Chen, Bing-Hui
    Huang, Jing-Jun
    Huang, Wen-Sou
    Cai, Ming-Yue
    Zhou, Jing-Wen
    Guo, Yong-Jian
    Zhu, Kang-Shun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (04) : 484 - 493
  • [45] A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib
    de la Torre, Manuel A.
    Buades-Mateu, Juan
    de la Rosa, Pedro A.
    Lue, Alberto
    Bustamante, Francisco J.
    Serrano, Maria T.
    Testillano, Milagros
    Lorente, Sara
    Arenas, Juan I.
    Gil, Cristina
    Inarrairaegui, Mercedes
    Sangro, Bruno
    LIVER INTERNATIONAL, 2016, 36 (08) : 1206 - 1212
  • [46] Serial alpha-fetoprotein evaluation and survival in hepatocellular carcinoma patients treated with sorafenib
    Personeni, N.
    Bozzarelli, S.
    Giordano, L.
    Rimassa, L.
    Pressiani, T.
    Tronconi, M. C.
    Sclafani, F.
    Carnaghi, C.
    Santoro, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 394 - 395
  • [47] IMPROVED SURVIVAL PREDICTION AND COMPARISON OF PROGNOSTIC MODELS FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB
    Labeur, Tim
    Berhane, Sarah
    Edeline, Julien
    Blanc, Jean-Frederic
    Bettinger, Dominik
    Meyer, Timothy
    van Vugt, Jeroen
    Ten Cate, David
    De Man, Robert A.
    Eskens, Ferry
    Cucchetti, Alessandro
    Van Delden, Otto
    Klumpen, Heinz-Josef
    Takkenberg, Robert Bart
    Johnson, Philip
    HEPATOLOGY, 2019, 70 : 525A - 526A
  • [48] Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Pomej, Katharina
    Scheiner, Bernhard
    Park, Dabin
    Bauer, David
    Balcar, Lorenz
    Meischl, Tobias
    Mandorfer, Mattias
    Reiberger, Thomas
    Muller, Christian
    Trauner, Michael
    Pinter, Matthias
    CANCERS, 2020, 12 (10) : 1 - 14
  • [49] Sorafenib-related adverse events predict survival in HCC treated with sorafenib combined with TACE
    Yang, Man
    Qi, Xingshun
    Liu, Ziwei
    Nie, Yongzhan
    Han, Guohong
    Wu, Kaichun
    Fan, Daiming
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 386 - 386
  • [50] Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib
    Cabibbo, Giuseppe
    Rolle, Emanuela
    De Giorgio, Massimo
    Genco, Chiara
    Pressiani, Tiziana
    Spada, Francesca
    Sacco, Rodolfo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (12) : 1807 - 1816